Aurinia Pharmaceuticals/$AUPH
1D1W1MYTD1Y5YMAX
Capital at risk
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
- Ticker
- $AUPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 128
- Headquarters
- Edmonton, Canada
- Website
- www.auriniapharma.com
AUPH Metrics
BasicAdvanced
$2.3B
7.36
$2.30
1.40
-
Price and volume
Market cap
$2.3B
Beta
1.4
52-week high
$19.25
52-week low
$10.34
Average daily volume
1M
Financial strength
Current ratio
5.419
Quick ratio
4.857
Long term debt to equity
0.075
Total debt to equity
0.104
Interest coverage (TTM)
39.08%
Profitability
EBITDA (TTM)
179.826
Gross margin (TTM)
78.02%
Net profit margin (TTM)
100.84%
Operating margin (TTM)
51.51%
Effective tax rate (TTM)
-95.88%
Revenue per employee (TTM)
$2,430,000
Management effectiveness
Return on assets (TTM)
15.49%
Return on equity (TTM)
66.12%
Valuation
Price to earnings (TTM)
7.364
Price to revenue (TTM)
7.162
Price to book
3.67
Price to tangible book (TTM)
3.69
Price to free cash flow (TTM)
12.743
Free cash flow yield (TTM)
7.85%
Free cash flow per share (TTM)
1.331
Growth
Revenue change (TTM)
19.76%
Earnings per share change (TTM)
447.94%
3-year revenue growth (CAGR)
24.84%
10-year revenue growth (CAGR)
106.03%
3-year earnings per share growth (CAGR)
65.25%
10-year earnings per share growth (CAGR)
16.05%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
Analyst projections of the future price of Aurinia Pharmaceuticals stock.
Bulls say / Bears say
Q2 LUPKYNIS sales rose 19% to $79.4 million and first-half sales rose 21% to $153.0 million; net income and operating cash flow also increased sharply. Reiterated 2026 revenue guidance of $315 million to $325 million points to continued double-digit growth and self-funding potential. (AP News)
Teva’s settlement recognises Aurinia’s patents as valid and enforceable and delays its generic until at least 7 December 2036, subject to contingencies and FDA approval. That gives LUPKYNIS a much clearer cash-generation runway in the United States. (Aurinia Pharmaceuticals, Fierce Pharma)
A new AURORA 1 analysis reported a statistically significant 53% reduction in the risk of a renal-related event or death with LUPKYNIS. That strengthens the drug’s clinical case and may support prescribing as competition grows. (BioSpace)
LUPKYNIS remains Aurinia’s lone marketed product, so a sales slowdown, safety issue or payer pressure would affect nearly the whole business. The Teva settlement does not remove the risk from other generic challengers, with litigation still ongoing against several companies. (Fierce Pharma, Aurinia Pharmaceuticals)
Competition is intensifying in lupus nephritis from Roche’s Gazyva and established biologics such as GSK’s Benlysta and AstraZeneca’s Saphnelo. Even with oral convenience, greater choice could make future growth and pricing harder to sustain. (Fierce Pharma)
Diversification remains unproven: PRESERVE is a newly initiated Phase 4 study, while aritinercept is still in clinical development and has no approved revenue. Recent coverage also notes limited clarity on the timelines and strategy for the Kezar assets, leaving investors exposed to trial and execution risk. (AP News, Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
AUPH News
AllArticlesVideos
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Benzinga4 weeks ago
Aurinia Settles Patent Litigation with Teva
Business Wire4 weeks ago
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Business Wire2 months ago
Funds containing AUPH
AllUSDEURGBP
Fund name | Fund size | $AUPH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.20% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.20% |
iShares Healthcare Innovation£DRDR | £1B | 0.20% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.